Plain-English translation of NCT05498792 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called combined with two established immunotherapy medications ( and ) in patients with advanced melanoma. The study is small and early-stage, focusing on whether the medication combination is safe and whether patients can tolerate it without serious side effects. Researchers will test different dose levels to find the right balance.
Melanoma is a serious form of skin cancer, and while existing immunotherapies help some patients, not everyone responds well or stays in remission. This trial explores whether adding the new medication to the current treatment approach might improve outcomes by working in a different way to help the immune system fight the cancer.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous (IV) infusions of the medication combination in 8-week treatment cycles. The new medication is given on specific days (1 and 8), while the two established immunotherapy drugs are given on other scheduled days within each cycle. You would need to return for multiple biopsies and blood draws throughout the study so researchers can monitor how your tumor responds and check for side effects. The entire study involves close medical monitoring to ensure your safety.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States